Those women who have early menopause have major cardiovascular and metabolic risk. The menopause below 40 years of age has been associated to increase in the risk of early beginning of osteoporosis, cardiovascular disease and diabetes mellitus, disorders characterized by hyperglycemia and glucose intolerance due to deficiency of insulin, decrease of the effectiveness of its action or both. The menopausal hormone therapy is the principal therapeutic tool, with the aim to contribute estrogens to suppress the clinical symptomatology and to make a favorably impact on the estrogen-dependent tissues. The existing data regarding menopausal hormone therapy in women experiencing menopause at the median age should not be extrapolated to women experiencing premature menopause.